
Pozdeutinurad Durability and Kidney Safety, With Puja Khanna, MD, MPH
Twelve-month REDUCE-2 data on deeper serum urate targets, renal adverse events and the flare and tophi readouts still to come.
Pozdeutinurad (AR882), an investigational once daily oral URAT1 inhibitor, sustained serum urate lowering through 12 months in the phase 3 REDUCE-2 trial, according to late-breaking data presented at the American College of Rheumatology (ACR)
The global, double-blind, placebo-controlled trial randomized 811 adults with
Treatment-emergent adverse events were reported in 60.7% of patients receiving 75 mg, 61.7% receiving 50 mg and 60.9% receiving placebo.² The trial also tracked renal events, including kidney stones and acute kidney injury, across all 3 arms.¹
“The REDUCE-2 results demonstrated clinically meaningful and durable serum urate lowering over 12 months, with a safety profile comparable to placebo, supporting the potential of pozdeutinurad as a treatment option for patients living with uncontrolled gout,” Puja P. Khanna, MD, MPH, professor of medicine in the Division of Rheumatology at the University of Michigan and a REDUCE-2 investigator, said in a statement.²
Outcomes on gout flares and tophus size, along with data from the companion REDUCE-1 trial, are still to come. In a written interview with HCPLive, Khanna discusses the depth and durability of urate lowering, how clinicians should read the renal safety data and the open questions facing the pozdeutinurad program.
Q&A: Pozdeutinurad Renal Safety and Deeper Serum Urate Targets
HCPLive: What do the 12-month data tell us about the durability of serum urate lowering with pozdeutinurad, including at deeper targets below 6 mg/dL?
Puja P. Khanna, MD, MPH: The data demonstrate that serum urate reductions with pozdeutinurad occurred rapidly, and most importantly, this effect was sustained through month 12. Furthermore, the results were not limited to achieving the standard target of below 6 mg/dL. Across the evaluated thresholds, greater proportions of patients treated with pozdeutinurad achieved serum urate levels below 5, 4 and 3 mg/dL compared with placebo.
Taken together, these findings demonstrate both the depth and durability of serum urate lowering observed in REDUCE-2.
HCPLive: How should clinicians interpret the safety findings, particularly with respect to kidney function, given prior experience with URAT1 inhibitors?
Puja P. Khanna, MD, MPH: The overall safety findings from REDUCE-2 were encouraging, with the incidence of treatment-emergent adverse events similar across treatment groups: 60.7% with pozdeutinurad 75 mg, 61.7% with 50 mg and 60.9% with placebo.
Looking specifically at renal events, treatment-related renal adverse events occurred in 1.8%, 2.2% and 1.2% of patients in the 75 mg, 50 mg and placebo groups, respectively. Renal stones were reported in 0.9%, 1.8% and 0.6%, respectively, while acute kidney injury occurred in 0%, 0.3% and 0.6%, respectively. So these events were far fewer overall compared with the general gout population, which has a higher risk of stones to begin with.
Importantly, we should not make direct comparisons with prior URAT1 inhibitors based on these data. There have been no head-to-head trials, so the appropriate focus is on the safety profile observed in REDUCE-2 and on the totality of evidence as the phase 3 program progresses.
HCPLive: What questions remain unanswered, including for outcomes such as flares and tophi, and what comes next for the pozdeutinurad program?
Puja P. Khanna, MD, MPH: REDUCE-2 provides important phase 3 evidence on serum urate efficacy and safety, but there are additional outcomes still to come. Specifically, data on gout flares and reduction in tophus size, as well as stratification in patients with CKD, are expected to be presented at scientific congresses in 2027, so it would be premature to draw conclusions about those outcomes based on the data presented at ACR.
The broader phase 3 program includes both REDUCE-1 and REDUCE-2, two 12-month, randomized, double-blind, placebo-controlled studies evaluating pozdeutinurad in patients with gout, including those with uncontrolled gout and tophaceous disease. The totality of those data will inform the next steps for the program.
Topline REDUCE-1 data are expected in early 2027, providing additional evidence on efficacy, safety and tolerability, and a regulatory filing remains on track for mid-2027.
Editors’ Note: Khanna reports relevant disclosures with Amgen, Arthrosi, Crystalys Therapeutics and Sobi. This transcript has been edited for grammar and clarity using artificial intelligence tools.
REFERENCES:
Khanna P, Mandell B, Keenan R, et al. Treatment with URAT1 inhibitor pozdeutinurad (AR882) in a phase 3, double-blind, randomized study lowers serum urate levels in participants with gout [abstract LB20]. Arthritis Rheumatol. 2026;78(suppl 9). Accessed November 19, 2026.
https://acrabstracts.org/abstract/treatment-with-urat1-inhibitor-pozdeutinurad-ar882-in-a-phase-3-double-blind-randomized-study-lowers-serum-urate-levels-in-participants-with-gout/ Sobi. Late-breaking phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad. Published October 29, 2026. Accessed November 19, 2026.
https://www.prnewswire.co.uk/news-releases/late-breaking-phase-3-reduce-2-data-show-clinically-meaningful-and-durable-serum-urate-lowering-with-pozdeutinurad-302923286.html
Related to this article







